Screening and identification of recombinant anti-idiotypic antibody against monoclonal antibody MGb1
10.3969/j.issn.1000-8861.2006.01.025
- VernacularTitle:针对单克隆抗体MGb1的重组抗独特型抗体的筛选与鉴定
- Author:
Yingru ZHENG
;
Rongfen LI
;
Li LI
;
Gang HUANG
;
Li ZHANG
;
Daqiang HU
- Publication Type:Journal Article
- Keywords:
Gastric carcinoma;
Anti-idiotypic antibody;
Phage display technique;
Tumor vaccine
- From:
Immunological Journal
2006;(1):86-89
- CountryChina
- Language:Chinese
-
Abstract:
Objective T9 provide candidate molecules for developing recombinant anti-idiotypic antibody (anti-Id) vaccine of gastric carcinoma by selection of recombinant anti-Id to monoclonal antibody ( McAb) MGb1 directed against the cancer with phage display technique.Methods Balb/c mice were immunized with MGb1 and the mRNA was isolated from the spleens of the immunized mice. The VL and VH cDNAs of the antibody were amplified separately by RT-PCR and assembled into ScFv DNAs with a linker DNA. The ScFv DNAs were ligated into the phagemid vector pCANTAB5E and the ligated sample was transformed into competent E. coli TG1. The transformed cells were infected with M13KO7 helper phage to yield recombinant phage antibody ScFv library. After four rounds of biopanning to the library with MGb1, the MGb1-positive clones were selected from the enriched phages by ELISA. The types of the anti-Id ScFv displayed on the selected phage clones were preliminarily identified by competition ELISA. Results The VL and VH cDNAs was about 320 bp and 340 bp, respectively. The ScFv DNA were about 750 bp. After four rounds panning to the phage antibody ScFv library with MGb1, 18 MGb1-positive phage clones displayed anti-Id ScFv were selected from 50 pre-selected phage clones, among which 4 clones displayed β or γ type anti-Id ScFv. Conclusion The phagedisplayed anti-Id ScFvs to McAb MGb1 are successfully selected by recombinant phage antibody technique, which might lay a foundation for screening the anti-Id ScFv possessing the characteristics of inducing anti-gastric carcinoma immunity.
